DocDollars

Cumberland Pharmaceuticals, Inc.

TN · United States · Reporting entity ID 100000005673

Total reported 2019–2025
$6.33M
#631 of 2,960 reporting companies — 0% of all reported industry payments
$2.48M in general payments across 29,774 records, plus $3.80M in research funding across 491 records.

How it breaks down

General payments $2,478,318
Research funding $3,802,888
Ownership & investment $45,540

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Cumberland Pharmaceuticals, Inc. reported $6.33M to US doctors and teaching hospitals from 2019 to 2025, ranking #631 of 2,960 reporting companies. 60% of that was research funding and 40% general payments such as consulting, speaking, food and travel. 29,774 general payment records and 491 research records were filed.

Common questions about Cumberland Pharmaceuticals, Inc.

How much has Cumberland Pharmaceuticals, Inc. paid US doctors?

Cumberland Pharmaceuticals, Inc. reported $6,326,746 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $2,478,318 in general payments, $3,802,888 in research funding and $45,540 in ownership and investment interests.

How does Cumberland Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #631 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Cumberland Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.